



NDA 018469/S-056

**SUPPLEMENT APPROVAL**

Alcon Laboratories, Inc.  
Attention: Suzanne Cadden MSc  
Head of Regulatory Affairs - USA  
6201 South Freeway  
Fort Worth, TX 76134

Dear Ms. Cadden:

Please refer to your Supplemental New Drug Application (sNDA) dated and received January 19, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for BSS PLUS Sterile Irrigating Solution (balanced salt solution enriched with bicarbonate, dextrose, and glutathione).

This Prior Approval supplemental new drug application proposes the removal of the sentence “Do not use additives other than the BSS PLUS Concentrate Part II (20 mL) provided with this bottle” from the reconstitution directions section of the label for the 500 mL (Part I) bottle container label and the 250 mL (Part II) bottle container label.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling package insert, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **IMMEDIATE CONTAINER LABELS**

Submit final printed immediate container labels that are identical to the enclosed immediate container labels submitted on January 19, 2016, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Container Labels for approved NDA 018469/S-056.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lois Almoza, M.S., Regulatory Health Project Manager, at (301) 796-1600.

Sincerely,

*{See appended electronic signature page}*

Wiley A. Chambers, MD  
Deputy Director  
Division of Transplant and Ophthalmology  
Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

WILEY A CHAMBERS  
04/27/2016